This is a preview of subscription content, log in via an institution to check access.
Notes
2012 US dollars
Reference
Klag N, et al. Is the routine use of bevacizumab in the treatment of women with advanced or recurrent cancer of the cervix sustainable? ClinicoEconomics and Outcomes Research 2016: 287-291, No. 8, 21 Jun 2016. Available from: URL: https://dx.doi.org/10.2147/CEOR.S71218
Rights and permissions
About this article
Cite this article
Routine use of bevacizumab for cervical cancer not sustainable. PharmacoEcon Outcomes News 756, 28 (2016). https://doi.org/10.1007/s40274-016-3177-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-016-3177-z